AmBisome Drug Interactions

No specific interaction studies have been performed with AmBisome. Although no clinically significant interactions of AmBisome with other drugs have been reported in clinical trials, patients requiring concomitant drug therapy should be monitored closely.
Conventional amphotericin has been reported to interact with antineoplastic agents and nephrotoxic drugs. In view of the potential of amphotericin B to cause reduction in serum potassium, AmBisome, like amphotericin B, may increase the effects of digitalis glycosides or muscle relaxants or may increase the potassium loss in the case of concurrent administration of AmBisome and corticosteroids or corticotropin (ACTH).
Concurrent administration of AmBisome with other nephrotoxic agents eg, cyclosporin and aminoglycosides, may increase the risk of nephrotoxicity in some patients. However, in patients receiving concomitant cyclosporin and/or aminoglycosides, AmBisome was associated with significantly less nephrotoxicity as compared to amphotericin B.